Compare IDEXX Laboratories, Inc. (IDXX) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs iShares Core S&P 500 ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while iShares Core S&P 500 ETF trades at $781.9 (market cap $897.20B). The key difference: iShares Core S&P 500 ETF is far larger — about 22.2× IDEXX Laboratories, Inc.'s market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares Core S&P 500 ETF for 46 Days on average.
| IDXX | IVV | |
|---|---|---|
Market Cap | $40.43B | $897.20B |
Volume | 692,164 | 4,580,672 |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $782.58 |
52-Week Low | $504.70 | $634.93 |
Typical Hold Time | 46 Days | 46 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
IVV, tracking the S&P 500, trades at $781.97 with a slight 0.18% daily gain. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights mixed sentiment with concerns about profit growth slowing from 35% in 2026 to 15% in 2027 (24/7 Wall Street, 2026-10-03), though some analysts project a year-end rally (Citadel strategist, 2026-10-02). The ETF remains a core holding for broad market exposure amid ongoing economic uncertainties.
The outlook for IVV is cautiously optimistic, supported by bullish technicals and historical seasonal patterns. Key opportunities include potential upside from AI-driven earnings growth and index composition changes like Twilio's addition (Market Watch, 2026-10-01). Risks center on concentration in top holdings, rising interest rates, and geopolitical tensions that could dampen broader market performance. Investors should weigh the ETF's low-cost diversification against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
